Telephone sharing button Contact Us mailbox sharing button wuxixdc_info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Locations & Facilities

We are headquartered in Wuxi, China and maintain operations at three locations in Wuxi, Shanghai and Changzhou. These sites are proximately located within a 200-kilometer radius, or approximately a two-hour drive, which ease logistic coordination, simplify program management, and improve project efficiency, thereby working to reduce the overall time and costs of drug development.

 

We seek to expand our discovery, development and manufacturing capabilities and capacity at the Wuxi site, to encompass the full-spectrum of services for the antibody and payload-linker intermediates and the bioconjugate drug substance and drug product.  Our goal is to achieve self-sufficient operations, and establish the necessary manufacturing capacity to meet the needs of multiple late-stage bioconjugate projects. Outside of China, we are planning to establish a manufacturing base in Singapore to meet the growing demand for end-to-end bioconjugate CRDMO services and implement a “global dual sourcing” strategy, which supports continuous and timely provision of services and product supply to our customers around the globe.

  • Wuxi, China

    Primary Use

    Drug Substance/Drug Product

    GMP-compliant production

    Formulation and analytical development

    QC release and stability testing

    Capacity

    Conjugation drug substance production

    Conjugation drug substance production line (“XBCM1”) with single-use reactor systems ranging from five liters to 500 liters to produce up to 500 liters of conjugation drug substance.

    The dual-function GMP manufacturing facility XBCM2 offers end-to-end manufacturing services – from monoclonal antibody intermediates to ADC drug substance- meeting the demand for ADC drug substance manufacturing up to 2,000 liters.
     

    Conjugation drug product production

    The conjugation drug product (“XDP1”) facility is designed to produce the liquid and lyophilization dosage forms with the annual capacity of up to three million vials in an isolated filling line equipped with one 5 sq.m. lyophilizer and one 20 sq.m. lyophilizer.

    The bioconjugate drug product GMP manufacturing facility XDP2 provides complete production capacity for highly potent and aseptic products. With the ability to produce liquid and lyophilized formulations in sizes from 2R to 50R, it reaches an annual production capacity of 5 million vials.

  • Shanghai, China

    Primary Use

    Bioconjugate discovery and process development

    Laboratories for bioconjugate discovery and process development.
    Bioconjugate discovery, research and process development

    Analytical and formulation development

    Scale-up conjugation

    Capacity

    Discovery lab

    Laboratories for bioconjugate discovery and process development.
     

    Bioconjugate process development lab

    Laboratory-scale sample preparation to pilot-scale manufacturing of ADCs and other bioconjugates.

  • Changzhou, China

    Primary Use

    Payload-linker

    Discovery, research and process and analytical development

    Pilot-scale synthesis

    GMP-compliant production

    Capacity

    Payload-linker

    Laboratory with a field-tested containment design to safely handle highly potent compounds that are OEB5-rated materials.

    Equipped with reaction kettles for GMP-compliant production with capacity of up to 150 liters, enabling kilogram-scale production of payload-linkers.

  • Singapore(New Expansion Sites)

    Primary Use

    Clinical or commercial manufacturing of antibody intermediates, drug substance and drug product

    Capacity

    Antibody intermediates and drug substance production

    Dual-function XmAb/XBCM3 production line with capacity of producing 200 liters to 2,000 liters per batch for monoclonal antibody intermediates and up to 2,000 liters per batch of bioconjugate drug substance

    XBCM4 production line with capacity of up to 500 liters of bioconjugate drug substance per batch
     

    Conjugation drug product production

    Two drug product manufacturing lines with annual capacities of up to eight million vials and three million vials, respectively

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?